Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

LOXO ONCOLOGY, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2013-01-01

Employees: 1K

Market Cap: -

Website: http://www.loxooncology.com

Clinical Trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Pirtobrutinib

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-24

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 249

Registration Number: NCT06588478

Locations: 🇺🇸
Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸
City of Hope National Medical Center, Irvine, California, United States
🇺🇸
Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto, California, United States

and more 132 locations

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Phase 2

Withdrawn

Conditions: Relapsing Multiple Sclerosis
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Pirtobrutinib

First Posted Date: 2023-10-27

Last Posted Date: 2024-03-27

Lead Sponsor: Loxo Oncology, Inc.

Registration Number: NCT06104683

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Clinical Trial Network, Houston, Texas, United States
🇺🇸
Swedish Medical Center-501 E Hampden Ave, Seattle, Washington, United States

and more 1 locations

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib

First Posted Date: 2022-04-12

Last Posted Date: 2025-03-21

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 46

Registration Number: NCT05324124

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Leukemia, B-cell
Leukemia, Lymphocytic
Small Lymphocytic Lymphoma

Interventions: Drug: Pirtobrutinib
Drug: Ibrutinib

First Posted Date: 2022-02-24

Last Posted Date: 2025-06-11

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 725

Registration Number: NCT05254743

Locations: 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸
Alta Bates Summit Medical Center, Berkeley, California, United States

and more 173 locations

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin
Drug: Pirtobrutinib

First Posted Date: 2022-01-04

Last Posted Date: 2022-04-15

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 34

Registration Number: NCT05176314

Locations: 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Lymphocytic, Small
Lymphoma, Mantle-Cell
Waldenstrom Macroglobulinemia
Ritcher's Transformation, Syndrome

First Posted Date: 2021-12-29

Last Posted Date: 2024-12-18

Lead Sponsor: Loxo Oncology, Inc.

Registration Number: NCT05172700

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib

First Posted Date: 2021-11-29

Last Posted Date: 2025-03-17

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 42

Registration Number: NCT05136404

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LOXO-305
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2021-11-24

Last Posted Date: 2025-01-09

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 27

Registration Number: NCT05134337

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LOXO-305
Drug: Omeprazole

First Posted Date: 2021-11-24

Last Posted Date: 2025-01-10

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 10

Registration Number: NCT05134350

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib

First Posted Date: 2021-10-22

Last Posted Date: 2025-03-17

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 224

Registration Number: NCT05089019

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy